eligibility_summary
Eligible: adults 18–74 with ECOG 0–1, life expectancy >3 mo, path-confirmed colorectal cancer with liver-only metastases (RAS/BRAF WT, MSS), ≥1 measurable liver lesion (RECIST 1.1), no prior systemic therapy (adjuvant chemo allowed if >6 mo), initially unresectable liver mets but potentially convertible to R0/NED, adequate organ function, consent. Exclude: any extrahepatic/LN mets or primary recurrence, unresectable primary, refusal of surgery if R0 feasible.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT06322147 tests adding cetuximab to doublet/triplet chemotherapy as conversion therapy for unresectable, liver-limited right‑sided colon cancer (RAS/BRAF WT, MSS). Interventions: cetuximab (chimeric IgG1 anti‑EGFR monoclonal antibody) plus FOLFOX (oxaliplatin + 5‑FU + leucovorin), FOLFIRI (irinotecan + 5‑FU + leucovorin), XELOX (capecitabine + oxaliplatin), or mFOLFOXIRI (oxaliplatin + irinotecan + 5‑FU + leucovorin). Mechanisms: cetuximab blocks EGFR ligand binding, inhibiting MAPK/ERK and PI3K/AKT signaling and may trigger ADCC, oxaliplatin creates DNA crosslinks, irinotecan inhibits topoisomerase I, 5‑FU/capecitabine inhibit thymidylate synthase and incorporate into RNA/DNA, leucovorin enhances 5‑FU–TS binding. Targets: EGFR on colorectal tumor cells, downstream RAS‑RAF‑MEK‑ERK/PI3K‑AKT pathways, DNA replication/repair.